Firm
After five IP partners left the firm for White & Case, the IP market could yet see more laterals
Paul Chapman and Robert Lind, who are retiring from Marks & Clerk after 30-year careers, discuss workplace loyalty, client care, and why we should be optimistic but cautious about AI
UK firm Shakespeare Martineau, which secured victory for the Triton shower brand at the Court of Appeal, explains how it navigated a tricky test regarding patent claim scopes
The firm’s managing partner said the city is an ‘exciting hub of ideas and innovation’
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by InspicosJakob Pade Frederiksen of Inspicos says a Unified Patent Court decision not to stay a revocation action while a parallel EPO opposition proceeding takes place provides another indication of the court’s fast pace -
Sponsored by Tilleke & GibbinsSon Thai Hoang and Linh Thi Mai Nguyen of Tilleke & Gibbins highlight the strict stance taken by the Intellectual Property Office of Vietnam on assignments conflicting with trade names and join the calls for clearer guidance
-
Sponsored by Tilleke & GibbinsThe Central Intellectual Property and International Trade Court has confirmed that a design’s overall appearance should be considered when determining its eligibility for patent protection, report Nuttaphol Arammuang and Tanapong Pongburanakit of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law reports on a decision that should provide improved guidance in determining whether patents or approved drugs are eligible for a patent term extension in South Korea
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Shipra Alisha Philip of RNA, Technology and IP Attorneys analyse how a US ruling could affect digital libraries, e-book licensing, and public access to knowledge in India
-
Sponsored by Bird & BirdEmilia Zalewska and Andrzej Stelmachowski of Bird & Bird provide insights into two matters considered by the Unified Patent Court and a Polish court concerning the imminent infringement of patent rights in the pharmaceutical industry
